MedTrace Logo

Role of Exenatide in Type 1 Diabetes

NCT00456300 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if giving exenatide and insulin before a meal would lower blood sugars after the meal. This study may help in developing new treatments to help control high blood sugars after meals. This may help improve overall blood sugar control and prevent the long-term effects of diabetes.

Conditions

Interventions

DRUG

Exenatide

In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.

DRUG

Insulin

Each subject received a baseline study with insulin alone

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Rubina Heptulla, MD · Montefiore Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-03-31
Completion
2009-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456300 on ClinicalTrials.gov